Evogene Ltd EVGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EVGN is a good fit for your portfolio.
News
-
Lavie Bio Announces a Distribution Agreement with WinField United Canada for its Bio-Inoculant Seed Treatment Yalos™
-
Lavie Bio Announces Expansion of its Bio-Inoculant Product for Spring Wheat, Yalos™, to Durum and Barley
-
Evogene Reports Third Quarter 2023 Financial Results
-
Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial Results
-
Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023
-
Colors Farm, Evogene and Ben-Gurion University Collaborate to Establish Crustacean Gene Editing Technology
-
Evogene Provides Operational Update Amidst Current Security Situation in Israel
-
Casterra Delivers First Shipment of Castor Seeds to Africa
Trading Information
- Previous Close Price
- $0.84
- Day Range
- $0.82–0.86
- 52-Week Range
- $0.45–1.44
- Bid/Ask
- $0.81 / $0.86
- Market Cap
- $42.47 Mil
- Volume/Avg
- 323,587 / 124,657
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.36
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 137
- Website
- https://www.evogene.com
Valuation
|
Metric
|
EVGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.29 |
Price/Sales | 6.36 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EVGN
|
|---|---|
Quick Ratio | 6.24 |
Current Ratio | 6.25 |
Interest Coverage | −31.26 |
Quick Ratio
EVGN
Profitability
|
Metric
|
EVGN
|
|---|---|
Return on Assets (Normalized) | −37.81% |
Return on Equity (Normalized) | −92.05% |
Return on Invested Capital (Normalized) | −46.24% |
Return on Assets
EVGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hnhy | $445.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mjgvt | $91.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qsytkp | $91.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Gqrxt | $40.7 Bil | |
MRNA
| Moderna Inc | Brys | $30.7 Bil | |
ARGX
| argenx SE ADR | Jnlnm | $27.7 Bil | |
BNTX
| BioNTech SE ADR | Ktft | $24.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nntldy | $22.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xzhjst | $17.7 Bil | |
INCY
| Incyte Corp | Jztpzf | $12.4 Bil |